Jennica L Zaro

List of Publications by Year
in descending order

23 papers	1,992 citations	430874 18 h-index	642732 23 g-index
23 all docs	23 docs citations	23 times ranked	3590 citing authors

#	Article	IF	Citations
1	Fusion protein linkers: Property, design and functionality. Advanced Drug Delivery Reviews, 2013, 65, 1357-1369.	13.7	1,273
2	Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochemical and Biophysical Research Communications, 2003, 307, 241-247.	2.1	78
3	Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting. Journal of Controlled Release, 2018, 279, 147-156.	9.9	61
4	Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery. AAPS Journal, 2015, 17, 83-92.	4.4	52
5	Nuclear Localization of Cell-Penetrating Peptides Is Dependent on Endocytosis Rather Than Cytosolic Delivery in CHO Cells. Molecular Pharmaceutics, 2009, 6, 337-344.	4.6	51
6	Evidence that membrane transduction of oligoarginine does not require vesicle formation. Experimental Cell Research, 2005, 307, 164-173.	2.6	47
7	Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells. Molecular Pharmaceutics, 2016, 13, 262-271.	4.6	47
8	Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials, 2014, 35, 4082-4087.	11.4	42
9	Cationic and amphipathic cell-penetrating peptides (CPPs): Their structures and in vivo studies in drug delivery. Frontiers of Chemical Science and Engineering, 2015, 9, 407-427.	4.4	40
10	Interaction between Cell-Penetrating Peptides and Acid-Sensitive Anionic Oligopeptides as a Model for the Design of Targeted Drug Carriers. Molecular Pharmaceutics, 2014, 11, 1583-1590.	4.6	37
11	Membrane Transduction of Oligoarginine in HeLa Cells Is Not Mediated by Macropinocytosis. Molecular Pharmaceutics, 2006, 3, 181-186.	4.6	33
12	Effects of Receptor Binding on Plasma Half-Life of Bifunctional Transferrin Fusion Proteins. Molecular Pharmaceutics, 2011, 8, 457-465.	4.6	31
13	Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery. Journal of Controlled Release, 2012, 158, 357-361.	9.9	30
14	pH-dependent reversibly activatable cell-penetrating peptides improve the antitumor effect of artemisinin-loaded liposomes. Journal of Colloid and Interface Science, 2021, 586, 391-403.	9.4	28
15	Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativaL.). BMC Biotechnology, 2012, 12, 92.	3.3	23
16	Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production. Diabetes, 2014, 63, 1779-1788.	0.6	23
17	Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells. Journal of Controlled Release, 2005, 108, 409-417.	9.9	21
18	Characterization of Polyelectrolyte Complex Formation Between Anionic and Cationic Poly(amino) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.8	20

#	Article	IF	Citations
19	Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells. Journal of Controlled Release, 2011, 155, 386-392.	9.9	16
20	Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics. Tissue Barriers, 2016, 4, e1156804.	3.2	13
21	Characterization and Oral Delivery of Proinsulin-Transferrin Fusion Protein Expressed Using ExpressTec. International Journal of Molecular Sciences, 2018, 19, 378.	4.1	10
22	Proinsulinâ€“Transferrin Fusion Protein Exhibits a Prolonged and Selective Effect on the Control of Hepatic Glucose Production in an Experimental Model of Type 1 Diabetes. Molecular Pharmaceutics, 2016, 13, 2641-2646.	4.6	8
23	Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery. Biomaterials, 2017, 117, 24-31.	11.4	8